Printer Friendly

Boston Scientific Launches Visualisation System for Pancreatico-Biliary Disease Diagnosis.

M2 PHARMA-February 26, 2015-Boston Scientific Launches Visualisation System for Pancreatico-Biliary Disease Diagnosis

(C)2015 M2 COMMUNICATIONS

US-based medical device maker Boston Scientific Corp. (NYSE: BSX) has received 510(k) clearance and the first cases of the SpyGlass DS Direct Visualization System used for cholangioscopy and pancreatoscopy procedures, the company said on Thursday.

Boston Scientific said that the new SpyGlass DS System is built on the technology of the original SpyGlass System, and is designed to optimize procedural efficiency and productivity with improved ease of setup, ease of use and image quality.

More than one million people worldwide undergo endoscopic retrograde cholangiopancreatography procedures each year to diagnose and treat diseases and conditions of the liver, gallbladder, pancreas and bile ducts, the company said.

In the event that x-ray imaging is not sufficient to make a definitive diagnosis or therapeutic intervention requires direct visualisation, cholangioscopy or pancreatoscopy may be performed.

Cholangioscopy is the examination of the bile ducts using an endoscope to enable direct visualization of the biliary tree during ERCP while pancreatoscopy is the examination of the pancreatic ducts.

Direct visualisation of the bile and pancreatic ducts during ERCP can help obtain biopsy specimens, lead to the diagnosis of abnormalities, and guide stone therapy.

Launched in 2007, the original SpyGlass System helped re-establish cholangioscopy and pancreatoscopy as a valuable diagnostic and therapeutic procedure, the company said, by allowing a single physician to perform the procedure as well as guide devices to examine, diagnose and treat conditions such as gallstones and suspected malignancies of the biliary tree and pancreas.

The new SpyGlass DS System builds on this technology with enhanced features to further improve visualization and help simplify the procedure.

It consists of a fully integrated SpyScopeDS Access and Delivery Catheter, and a single-use scope to eliminate probe reprocessing and image degradation over multiple uses.

The integrated digital sensor provides superior imaging, far greater resolution and a 60% wider field of view than the first generation system.

In addition, the SpyGlass DS System offers physicians an integrated controller that fits on a standard ERCP cart for improved accessibility and 'plug and play' setup, helping to reduce procedure time.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 26, 2015
Words:367
Previous Article:Dectris Launches X-Ray Detectors for OEM use in Laboratory Diffractometers.
Next Article:Zeiss Launches New Version of Glaucoma Diagnostics and Management Platform.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters